HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors - Trial NCT06336707
Access comprehensive clinical trial information for NCT06336707 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hansoh BioMedical R&D Company and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 1048 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hansoh BioMedical R&D Company
Timeline & Enrollment
Phase 1
Apr 08, 2024
Apr 08, 2028
Primary Outcome
Maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-20089 in combination therapy
Summary
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1
 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a
 protease-cleavable linker, with an average drug-to-antibody ratio of about 6.
 
 This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability,
 pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents
 (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with
 advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336707
Non-Device Trial